{"id":12157,"date":"2025-08-07T19:59:35","date_gmt":"2025-08-07T10:59:35","guid":{"rendered":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/?p=12157"},"modified":"2025-10-02T17:09:33","modified_gmt":"2025-10-02T08:09:33","slug":"%e3%80%90research-highlight%e3%80%91-spera-pharma-at-omcos-xx%e2%85%b1-exhibition-poster-presentation","status":"publish","type":"post","link":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/en\/news\/p12157\/","title":{"rendered":"\u3010Research Highlight\u3011 SPERA PHARMA at OMCOS XX\u2161 \u2013 Exhibition & Poster Presentation"},"content":{"rendered":"

We are pleased to announce that researchers from SPERA PHARMA (Chemical R&D Laboratory) \u2014Keiyo Nakai, Takahiro Konishi, Mitsuhisa Ymano, and Kuniyoshi Miki\u2014will present their research findings in a poster session at the 22nd International Symposium on Organometallic Chemistry Directed Towards Organic Synthesis (OMCOS XX\u2161), to be held at Hotel Granvia Kyoto on September 1\u20135, 2025.<\/p>\n

 <\/p>\n

\u2605OMCOS XX\u2161<\/a><\/strong><\/p>\n

\u3000\u3000\u3000DATE\uff1a\u3000\u3000September 1-5, 2025<\/strong>
\n\u3000\u3000\u3000VENUE\uff1a\u3000Hotel Granvia Kyoto, Japan<\/strong>
\n\u3000\u3000\u3000Booth No.\uff1a\u30003
\n<\/strong><\/p>\n

 <\/p>\n

\u2605Poster presentation<\/span><\/strong><\/p>\n

\u3000\u3000\u3000Poster Title\uff1a\u3000\u3010PB-080\u30113D ED\/MicroED structural analysis of various organometallic complexes<\/strong><\/p>\n

\u3000\u3000\u3000Authors\uff1a\u3000\u3007Keiyo Nakaia<\/sup>, Takahiro Konishia<\/sup>, Takashi Kikuchib<\/sup>, Kuniyoshi Mikia<\/sup>,
\n<\/strong>\u00a0 \u00a0 \u3000\u3000\u3000 \u3000\u3000\u3000\u3000 \u00a0Mitsuhisa Yamanoa<\/sup><\/strong>
\n\u3000\u3000\u3000\u3000\u3000 \u3000\u3000\u3000 \uff08a<\/sup> SPERA Pharma, Inc., b<\/sup> Rigaku Corporation\uff09<\/strong><\/p>\n

 <\/p>\n

SPERA PHARMA has recently introduced a state-of-the-art 3D ED\/MicroED crystallographic structure analysis system (Synergy-ED, manufactured by Rigaku Corporation and JEOL Ltd.), enhancing our capabilities in resolving complex crystallographic challenges through advanced structural analysis.
\nIn parallel, we have inherited extensive expertise from our time at Takeda Pharmaceutical and continue to advance asymmetric reduction reactions using a variety of chiral ligands. Notably, our screening capabilities for ruthenium-catalyzed asymmetric reductions are recognized as among the best in the world.
\nWe conducted a feasibility study to evaluate the structural determination power of 3D ED\/MicroED in analyzing organometallic complexes. The study confirmed that this technology enables rapid determination of absolute stereochemistry\u2014an area that traditionally required considerable time\u2014significantly streamlining the structural analysis process. We sincerely hope that these steady efforts in structure determination will contribute to the development of various reactions using organometallic catalysts.<\/p>\n

 <\/p>\n

At SPERA PHARMA, we apply this analytical technology not only to organometallic complexes but also to the elucidation of crystal polymorphs, APIs in formulations, salts\/co-crystals, and metabolites. Through providing accurate and timely structural insights, we remain committed to empowering our clients in overcoming their development challenges.<\/p>\n

 <\/p>\n

We sincerely look forward to welcoming you to our exhibition booth and poster presentation.
\nFor inquiries regarding this service, please click the button below.<\/p>\n

Inquiry<\/span><\/a>\n","protected":false},"excerpt":{"rendered":"

We are pleased to announce that researchers from SPERA PHARMA (Chemical R&D Laboratory) \u2014Keiyo Nakai, Taka […]<\/p>\n","protected":false},"author":2,"featured_media":12187,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/?p=12151","footnotes":""},"categories":[6],"tags":[88,74,85],"class_list":["post-12157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-88","tag-microed","tag-spera-pharma","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/posts\/12157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/comments?post=12157"}],"version-history":[{"count":32,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/posts\/12157\/revisions"}],"predecessor-version":[{"id":12207,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/posts\/12157\/revisions\/12207"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/media\/12187"}],"wp:attachment":[{"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/media?parent=12157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/categories?post=12157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heuristic-ardinghelli.153-122-123-210.plesk.page\/wp-json\/wp\/v2\/tags?post=12157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}